A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Participants With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy aged 12 years and above.
The duration of participants participation will be up to 4 weeks for screening, treatment until clinically significant progression of disease, and 4 weeks of safety follow-up, and then long-term follow-up every 12 weeks.1 Cycle = 28 days.

开始日期2025-06-16

申办/合作机构

Kadmon Holdings, Inc.

NCT07006506

/ Recruiting临床2期IIT

Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation

The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.

开始日期2025-05-21

申办/合作机构

Memorial Sloan Kettering Cancer Center

NCT06751602

/ Not yet recruiting临床2期IIT

A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Belumosudil for the Abrogation of Interstitial Fibrosis and Tubular Atrophy in de Novo Kidney Transplant Recipients

This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of belumosudil (brand name- REZUROCK®) on the background of standard immunosuppression will prevent fibrosis in the kidney transplant. Interstitial expansion is the precursor of interstitial fibrosis and graft loss. The hypothesis underlying the study is that abgrogating the fibrogenic effects of the RhoA pathway with belumosudil will reduce structural damage in transplanted kidneys and possible subsequent transplant failure.

开始日期2025-04-15

申办/合作机构

The Methodist Hospital Research Institute

100 项与甲磺酸贝舒地尔相关的临床结果

登录后查看更多信息

100 项与甲磺酸贝舒地尔相关的转化医学

登录后查看更多信息

100 项与甲磺酸贝舒地尔相关的专利（医药）

登录后查看更多信息

171

项与甲磺酸贝舒地尔相关的文献（医药）

2025-08-01·BIOMEDICAL CHROMATOGRAPHY

Identification and Characterization of Belumosudil Degradation Impurities Using the LC–MS/MS Method and Its Validation

Article

作者: Koganti, Kalyani ; Sattu, Naga Raju ; Amara Babu, Namburi L. A. ; Rao, Koya Prabhakara

ABSTRACT:

For the treatment of chronic graft‐versus‐host disease (cGVHD), belumosudil (BSL) used as an important therapeutic agent. The stability study of BSL mainly emphasizes the identification and quantification of degradation products formed under different stress conditions such as hydrolysis (acidic, basic, and neutral), oxidation, photolysis, and thermal degradation according to ICH guidelines. In this study, BSL has demonstrated significant deterioration in acidic and basic hydrolysis as well as oxidative stress conditions, while it remains stable in neutral hydrolysis, photolytic, and thermal stress conditions. An LC–MS/MS method for the detection and quantification of BSL degradation products was developed and validated in accordance with ICH Q2 (R1). By using a 25‐min gradient program and an Ascentis Express‐F5 column (150 × 4.6 mm, 5 μm), this method effectively separated the analyte from its degradation impurities. Moreover, exposure of BSL to oxidative, basic, and acidic conditions resulted in four different degradation products. The formed degradation compounds were identified by using mass spectral data, and plausible fragmentation patterns were proposed by using mass data. This validated stability‐indicating assay method confirms its appropriateness for routine analysis and stability investigations of BSL.

2025-07-22·Blood Advances

Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

Article

作者: Alousi, Amin S. ; Mays, Jacqueline W. ; Pavletic, Steven Z. ; Yao, Yu ; Javaid, Ayesha ; Sharma, Rubina ; Ji, Ran ; Pusic, Iskra ; Hu, Beifang ; Holtzman, Noa G. ; Vigneswaran, Nadarajah ; Lee, Stephanie J. ; Cutler, Corey ; Mehta, Rohtesh S. ; Macé, Sandrine ; Mody, Drashty P. ; Schueller, Olivier ; Treister, Nathaniel ; Marshall, Kathy ; Boksa, Francis ; Costa-da-Silva, Ana C. ; Blazar, Bruce R.

Abstract:

Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil–containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2 inhibition reduces blood interleukin-17 (IL-17) activity and promotes regulatory T-cell (Treg cell) recovery. However, these studies did not evaluate immune responses within cGVHD-affected tissues. This study assessed tissue-level immune dynamics in 20 patients with oral cGVHD from the phase 2 ROCKstar trial, before and after 6 months of belumosudil treatment, focusing on key effector sites (oral mucosa [OM], minor salivary glands [MSGs], and skin) and the peripheral blood. After belumosudil treatment, reduction in collagen was observed in OM in parallel with decreased IL-17+ cell frequency in both OM (n = 14 pairs) and MSG (n = 11 pairs). IL-17 was primarily produced by non–T cells in the oral tissues. Immune cell frequencies in the OM decreased after treatment, whereas CD4 Treg cells increased in both the MSG and blood. Per overall or mouth-specific clinical response criteria, responders to belumosudil exhibited a reduction in collagen type I and IL-17 in the OM. Additionally, salivary transforming growth factor β1 (TGF-β1), a critical driver of fibrosis, decreased significantly, with a strong correlation observed between TGF-β1 and IL-17 levels. These findings illustrate the tissue-level response to belumosudil therapy and suggest that there is a reduction in tissue fibrosis and inflammation, thereby highlighting the therapeutic impact of ROCK2 inhibition in mitigating cGVHD. The ROCKstar study was registered at www.ClinicalTrials.gov as #NCT03640481.

2025-07-01·CTS-Clinical and Translational Science

Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment

Article

作者: Teichert, Lenore ; Patel, Jeegar ; Lohmer, Lauren ; Esposito, Virginie ; Sahi, Jasminder ; Schueller, Olivier ; Beck, Felix

ABSTRACT:

Belumosudil, an orally administered Rho‐associated coiled‐coil–containing protein kinase 2 selective inhibitor drug for treatment of chronic graft‐versus‐host disease (GVHD), is predominantly eliminated via the liver. This phase 1, open‐label, non‐randomized, parallel‐group study (NCT04166942) evaluated belumosudil pharmacokinetics and safety after a single 200‐mg dose in participants with mild, moderate, or severe hepatic impairment (Child‐Pugh classification), matched with healthy participants with normal hepatic function. M1 and M2 metabolites were also assessed. Geometric least squares mean (GLSM) ratios (90% confidence intervals [CI]) for belumosudil area under the plasma concentration‐time curve (AUC) from time 0 to the time to infinity (AUC0‐∞), AUC to the time of last measurable concentration (AUC0−t), and maximum concentration (Cmax) were 1.36 (0.83–2.21), 1.48 (0.96–2.28), and 1.20 (0.91–1.58), respectively, for the mild impairment group, and 1.51 (0.98–2.33), 1.50 (0.97–2.31), and 0.94 (0.60–1.48), respectively, for the moderate impairment group. Severe hepatic impairment markedly increased belumosudil AUC0–∞ and AUC0–t but had no apparent effect on Cmax; GLSM ratios (90% CI) were 4.21 (2.20–8.06), 3.23 (1.53–6.81), and 1.32 (0.90–1.96), respectively. A post hoc analysis was conducted using the National Cancer Institute‐Organ Dysfunction Working Group (NCI‐ODWG) classification for hepatic impairment. Assessment by NCI‐ODWG criteria, compared with Child‐Pugh criteria, revealed a higher range of exposure in participants with moderate hepatic impairment. Belumosudil can be taken by patients with mild hepatic impairment without dose adjustment; avoid use in patients with moderate hepatic impairment (Child‐Pugh B) or severe hepatic impairment (Child‐Pugh C) without liver GVHD.

127

项与甲磺酸贝舒地尔相关的新闻（医药）

2025-06-12

·PRNewswire

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus host disease market and creating significant growth opportunities. LAS VEGAS, June 12, 2025 /PRNewswire/ -- Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient's adaptive immune systems. It typically manifests in two main forms: acute (aGvHD) and chronic (cGvHD). As per DelveInsight's analysis, approximately 60,000 allogeneic transplants and around 55,000 GvHD cases occurred in the 7MM in 2024. These numbers are projected to grow at a notable CAGR over the forecast period from 2025 to 2034. Corticosteroids like prednisone and methylprednisolone are the primary first-line treatments, often combined with other immunosuppressants. Mild GcHD is managed with topical steroids, while systemic cases require stronger immunosuppressive therapy. Several treatments for GvHD have received FDA approval in the US, including ORENCIA (abatacept), JAKAFI/JAKAVI (ruxolitinib), IMBRUVICA (ibrutinib), and REZUROCK (belumosudil), among others. In the upcoming GvHD treatment market landscape, there are a plethora of companies investigating agents in various stages of development. To know more about the graft versus host disease clinical trials market, visit @ Graft versus Host Disease Market DelveInsight estimates that the market size for GvHD is expected to grow from USD 1.4 billion in 2024 with a significant CAGR of 8.2% by 2034. This anticipated growth is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies. The current pipeline for graft versus host disease includes a range of drugs with diverse mechanisms of action (MoA). CSL964 (Alpha 1 Antitrypsin), EQ001 (Itolizumab; Bmab600), MaaT013, and MC0518 are the most promising drugs that are in the late-stage of development for GvHD treatment. Ongoing research and current trials have the potential to change the GvHD market. Keen to know how the GvHD market will evolve by 2034? Find out @ Graft versus Host Disease (GvHD) Market Forecast Apart from this, several GvHD drugs currently in the early stages of development include RLS-0071 by ReAlta Life Sciences, Vimseltinib by Deciphera Pharmaceuticals, ASC-930 by ASC Therapeutics, RGI-2001 by REGiMMUNE, CYP-001 by Cynata Therapeutics, arsenic trioxide (As2O3) by BioSenic (Medsenic), TRX103 (Tregs) by Tr1X, TCD601 (Siplizumab) by ITB-MED, F-652 by Evive Biotech, RHPRG4 by Lubris BioPharma, XBI302 by Xbiome, RG6287 by Genentech, ALTB-168 by AltruBio, and SER-155 by Seres Therapeutics. Now, let's examine the late-stage pipeline therapies under investigation for GvHD treatment CSL Behring's ZEMAIRA CSL964 Alpha-1 Antitrypsin, an Alpha1-Proteinase Inhibitor (A1-PI) developed by CSL Behring, is being studied for the treatment of steroid-refractory acute graft-versus-host disease (aGvHD) and for the prevention of aGvHD in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). It is currently in Phase III clinical trials for the treatment of steroid-refractory aGvHD and is also being evaluated in Phase II/III trials for its potential in preventing aGvHD. Equillium/Biocon's EQ001 EQ001 (Itolizumab; Bmab600) is a first-in-class immune-modulating antibody that targets CD6 to suppress the activation and migration of harmful T cells responsible for releasing pro-inflammatory cytokines in autoimmune and inflammatory conditions such as GvHD, moderate-to-severe uncontrolled asthma, and lupus nephritis. By acting on the CD6-ALCAM signaling pathway, Itolizumab selectively inhibits pathogenic effector T cells (Teffs) while preserving regulatory T cells (Tregs), which are essential for immune system balance. Currently, EQ001 is undergoing a Phase III clinical trial in combination with corticosteroids as a first-line therapy for GvHD.In March 2025, Equillium reported topline Phase III EQUATOR trial results for itolizumab in first-line aGVHD. While the study did not show a meaningful difference in CR or ORR at Day 29 versus placebo, itolizumab demonstrated statistically significant and clinically meaningful improvements in longer-term outcomes, including CR at Day 99, duration of response, and failure-free survival. In April 2025, the FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway for itolizumab, citing limitations in the EQUATOR study data. Discover which therapies are expected to grab major GvHD market share @ Graft versus Host Disease Treatment Market MaaT Pharma's MaaT013 MaaT013 is a standardized, donor-derived microbiome ecosystem therapy characterized by high richness and diversity. It includes BUTYCORE, a consortium of bacterial species known for producing anti-inflammatory short-chain fatty acids. The therapy is designed to reestablish the balance between the patient's gut microbiome and immune system, aiming to enhance immune tolerance and responsiveness, thereby addressing steroid-resistant, gastrointestinal-dominant aGvHD. MaaT013 has been granted Orphan Drug Designation (ODD) by both the US FDA and the EMA. In December 2024, MaaT Pharma shared encouraging updated results from its Early Access Program at the ASH 2024 Annual Meeting. Subsequently, in January 2025, the company announced promising topline findings from the Phase III ARES trial, where MaaT013 achieved a 62% overall gastrointestinal response rate by Day 28, marking a significant advancement as a third-line treatment for GI-aGvHD. medac's MC0518 MC0518 is an investigational mesenchymal stromal cell (MSC) therapy developed by Medac GmbH, currently undergoing clinical trials for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) following allogeneic hematopoietic stem cell transplantation. This therapy leverages the immunomodulatory properties of MSCs to mitigate the severe inflammatory responses characteristic of SR-aGvHD, a condition where the donor's immune cells attack the recipient's tissues despite steroid treatment. The IDUNN trial, a pivotal Phase III study, is evaluating the efficacy and safety of MC0518 compared to the best available therapy (BAT) in pediatric and adolescent patients. The primary endpoint is the overall response rate (ORR) at Day 28, with secondary objectives including overall survival (OS) up to 24 months and freedom from treatment failure (FFTF) within six months. Preclinical assessments have demonstrated that MC0518 is well-tolerated, with no evidence of tumorigenicity or significant adverse effects in animal models. Discover more about drugs for GvHD in development @ Graft versus Host Disease Clinical Trials The anticipated launch of these emerging therapies for GvHD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GvHD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight's latest published market report, titled as Graft versus Host Disease Market Insight, Epidemiology, and Market Forecast – 2034 , will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the GvHD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The GvHD market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total allogenic transplant cases Total Graft Versus Host Disease Cases Type-specific Cases of Graft Versus Host Disease Acute Graft Versus Host Disease Cases by Grading Acute Graft Versus Host Disease Cases by Organ Involvement Chronic Graft Versus Host Disease Cases by Grading Chronic Graft Versus Host Disease Cases by Organ Involvement Total Treated Cases of Graft Versus Host Disease Mortality Adjusted Treated Cases of Graft Versus Host Disease The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM GvHD market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this GvHD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the GvHD market. Also, stay abreast of the mitigating factors to improve your market position in the GvHD therapeutic space. Related Reports Graft versus Host Disease Epidemiology Forecast Graft versus Host Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Graft versus Host Disease Pipeline Graft versus Host Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical, CTI BioPharma, ViGenCell, Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen , among others. Acute Graft versus Host Disease Pipeline Acute Graft versus Host Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute GvHD companies, including MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, Incyte Corporation , among others. Ocular Graft versus Host Disease Pipeline Ocular Graft versus Host Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ocular GvHD companies, including Cambium Medical Technologies, Glia LLC., Ocular Discovery, Selagine , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果免疫疗法突破性疗法孤儿药

2025-06-08

·信狐药迅

浙江杭煜1类新药索美来昔、三生国健IL-1β单抗提交上市申请|新受理（6.2-6.8）

本周药品注册受理数据，分门别类呈现，一目了然。(6.2-6.8）新药上市申请药品名称企业注册分类受理号硫酸索美来昔片浙江杭煜制药有限公司1CXHS2500061赖诺普利氨氯地平片四川尚锐生物医药有限公司2.4CXHS2500062呋喹替尼胶囊和记黄埔医药(上海)有限公司2.4CXHS2500060呋喹替尼胶囊和记黄埔医药(上海)有限公司2.4CXHS250005915价肺炎球菌结合疫苗北京智飞绿竹生物制药有限公司2.1CXSS2500059重组抗IL-1β人源化单克隆抗体注射液三生国健药业(上海)股份有限公司1CXSS2500060注射用维迪西妥单抗荣昌生物制药(烟台)股份有限公司2.2CXSS2500058新药临床申请药品名称企业注册分类受理号注射用HTMC0769上海壹典医药科技开发有限公司1CXHL2500546HSK47977片海思科医药集团股份有限公司1CXHL2500545HSK47977片海思科医药集团股份有限公司1CXHL2500544WJ22096片南京境奥生物医药科技有限公司1CXHL2500543WJ22096片南京境奥生物医药科技有限公司1CXHL2500542HRS-4508片江苏恒瑞医药股份有限公司1CXHL2500541HRS-4508片江苏恒瑞医药股份有限公司1CXHL2500540QL-H118片南京芩领医药科技有限公司1CXHL2500538MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500531MDI-1228_mesylate凝胶迈英诺医药科技(珠海)有限公司1CXHL2500530HB5凝胶北京中科先行医疗科技有限公司1CXHL2500536HB5凝胶北京中科先行医疗科技有限公司1CXHL2500535HB5凝胶北京中科先行医疗科技有限公司1CXHL2500534XC2309注射液浙江医药股份有限公司新昌制药厂1CXHL2500533D-2570片益方生物科技(上海)股份有限公司1CXHL2500529SN007干混悬剂上海惠永制药有限公司2.2CXHL2500539注射用硼[10B]法仑中子科学(重庆)研究院有限公司2.2CXHL2500532ZK062南京正科医药股份有限公司2.2CXHL2500528注射用多西他赛(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2500537注射用SSS50沈阳三生制药有限责任公司1CXSL2500458注射用LM-24C5礼新医药科技(上海)有限公司1CXSL2500457HJY-ATRQβ-001注射液武汉华纪元生物技术开发有限公司1CXSL2500463注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2500455UC101 CAR-T细胞注射液成都优赛诺生物科技有限公司1CXSL2500451LYN101注射液上海才致药成生物科技有限公司1CXSL2500456TI-0093注射液圆因(北京)生物科技有限公司1CXSL2500461KM1溶瘤痘苗病毒注射液深圳市华药康明生物药业有限责任公司1CXSL2500446SIBP-A10注射液上海生物制品研究所有限责任公司1CXSL2500449注射用DXC018杭州多禧生物科技有限公司1CXSL2500444替雷利珠单抗注射液广州百济神州生物制药有限公司2.1CXSL2500447贝伐珠单抗注射液苏州盛迪亚生物医药有限公司2.2CXSL2500450阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500448司普奇拜单抗注射液成都康诺行生物医药科技有限公司2.2CXSL2500454仿制药申请药品名称企业注册分类受理号盐酸异丙肾上腺素注射液江苏迪赛诺制药有限公司3CYHS2502023盐酸异丙肾上腺素注射液江苏迪赛诺制药有限公司3CYHS2502022叶酸注射液北京远方通达医药技术有限公司3CYHS2502020叶酸注射液北京远方通达医药技术有限公司3CYHS2502019比拉斯汀口服溶液嘉亨(珠海横琴)医药科技有限公司3CYHS2502018盐酸溴己新口服溶液湖南九典制药股份有限公司3CYHS2502016维生素K1注射液成都苑东生物制药股份有限公司3CYHS2502012硝普钠注射液河北一品制药股份有限公司3CYHS2502011碳酸司维拉姆干混悬剂山东百诺医药股份有限公司3CYHS2502009乙酰半胱氨酸片江西迪赛诺医药集团有限公司3CYHS2502008唑来膦酸注射液广东大翔制药有限公司3CYHS2502005米诺地尔搽剂山东朗诺制药有限公司3CYHS2502003米诺地尔搽剂山东朗诺制药有限公司3CYHS2502002西格列汀二甲双胍缓释片寿光富康制药有限公司3CYHS2501999多种微量元素注射液(I)成都欣捷高新技术开发股份有限公司3CYHS2501992联苯苄唑溶液浙江致新医药科技有限公司3CYHS2501987对乙酰氨基酚布洛芬片哈尔滨三联药业股份有限公司3CYHS2501980注射用头孢噻肟钠/氯化钠注射液湖南科伦制药有限公司3CYHS2501998注射用头孢噻肟钠/氯化钠注射液湖南科伦制药有限公司3CYHS2501997硝普钠注射液山东齐都药业有限公司3CYHS2501982硝普钠注射液山东齐都药业有限公司3CYHS2501981注射用氢化可的松琥珀酸钠沐源(安徽)药业有限公司3CYHS2501975注射用氢化可的松琥珀酸钠沐源(安徽)药业有限公司3CYHS2501974吡格列酮二甲双胍片浙江众延医药科技有限公司3CYHS2501972碳酸司维拉姆干混悬剂福建博悦医药科技有限公司3CYHS2501966米诺地尔搽剂江苏福邦药业有限公司3CYHS2501965布比卡因脂质体注射液浙江海昶生物医药技术有限公司3CYHS2501973枸橼酸托法替布缓释片北大医药股份有限公司4CYHS2502027恩格列净片德州博诚制药有限公司4CYHS2502026恩格列净片德州博诚制药有限公司4CYHS2502025氧韩城市红光制气有限责任公司4CYHS2502024玻璃酸钠滴眼液广州大光制药有限公司4CYHS2502021甲钴胺片河北宏鑫堂药业有限公司4CYHS2502017磷酸奥司他韦胶囊石家庄四药有限公司4CYHS2502015磷酸奥司他韦胶囊石家庄四药有限公司4CYHS2502014乙酰半胱氨酸注射液舒美奇成都生物科技有限公司4CYHS2502013硫酸氨基葡萄糖胶囊山东百诺医药股份有限公司4CYHS2502010利那洛肽胶囊苏州二叶制药有限公司4CYHS2502007唑来膦酸注射液广东大翔制药有限公司4CYHS2502006盐酸氨溴索注射液中国大冢制药有限公司4CYHS2502004地拉罗司分散片河北天成药业股份有限公司4CYHS2502001乙酰半胱氨酸注射液浙江昂利康制药股份有限公司4CYHS2502000盐酸羟考酮缓释片江苏恩华药业股份有限公司4CYHS2501993二十碳五烯酸乙酯软胶囊北京斯利安药业有限公司4CYHS2501995佩玛贝特片南京海鲸药业股份有限公司4CYHS2501994依折麦布阿托伐他汀钙片(I)华润赛科药业有限责任公司4CYHS2501991依折麦布阿托伐他汀钙片(II)华润赛科药业有限责任公司4CYHS2501990甲磺酸沙非胺片宁波美诺华天康药业有限公司4CYHS2501989甲磺酸沙非胺片宁波美诺华天康药业有限公司4CYHS2501988棕榈酸帕利哌酮注射液丽珠集团丽珠制药厂4CYHS2501986棕榈酸帕利哌酮注射液丽珠集团丽珠制药厂4CYHS2501985棕榈酸帕利哌酮注射液丽珠集团丽珠制药厂4CYHS2501984依西美坦片浙江亚瑟医药有限公司4CYHS2501983非洛地平缓释片河北爱普制药有限公司4CYHS2501996乙酰半胱氨酸注射液西藏诺泽生物医药有限公司4CYHS2501979左氧氟沙星滴眼液合肥华威药业有限公司4CYHS2501971盐酸氨溴索口服溶液广东南国药业有限公司4CYHS2501970盐酸氨溴索口服溶液广东南国药业有限公司4CYHS2501969阿达帕林过氧苯甲酰凝胶北京普祺医药科技股份有限公司4CYHS2501968阿达帕林过氧苯甲酰凝胶北京普祺医药科技股份有限公司4CYHS2501967他达拉非片浙江永太药业有限公司4CYHS2501964他达拉非片浙江永太药业有限公司4CYHS2501963尼可地尔片国药集团容生制药有限公司4CYHS2501962甲磺酸沙非胺片成都明德至远医药科技有限公司4CYHS2501961甲磺酸沙非胺片成都明德至远医药科技有限公司4CYHS2501960达格列净片重庆科瑞南海制药有限责任公司4CYHS2501959达格列净片重庆科瑞南海制药有限责任公司4CYHS2501958达格列净片合肥合源药业有限公司4CYHS2501978达格列净片合肥合源药业有限公司4CYHS2501977甲磺酸贝舒地尔片浙江华义制药有限公司4CYHS2501976盐酸毛果芸香碱滴眼液浙江莎普健康管理有限公司3CYHL2500107维生素D口服溶液厦门紫旭医药科技有限公司3CYHL2500105利多卡因丙胺卡因牙周凝胶深圳珐玛易药品科技有限公司3CYHL2500103布地奈德福莫特罗吸入粉雾剂(II)珠海瑞思普利医药科技有限公司4CYHL2500106多种油脂肪乳注射液(C6-24)成都国为生物医药有限公司4CYHL2500104流感病毒裂解疫苗武汉生物制品研究所有限责任公司3.3CXSL2500460流感病毒裂解疫苗武汉生物制品研究所有限责任公司3.3CXSL2500459度普利尤单抗注射液石药集团巨石生物制药有限公司3.3CXSL2500453度普利尤单抗注射液石药集团巨石生物制药有限公司3.3CXSL2500452SAL023注射液信立泰(苏州)药业有限公司3.3CXSL2500445进口申请药品名称企业注册分类受理号替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2500064替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2500063替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2500062替尔泊肽注射液Eli Lilly Nederland B.V.5.1JXHS2500061Clesrovimab注射液Merck Sharp & Dohme B.V.1JXSS2500071帕博利珠单抗注射液(皮下注射)Merck Sharp & Dohme B.V.2.1JXSS2500073帕博利珠单抗注射液(皮下注射)Merck Sharp & Dohme B.V.2.1JXSS2500072Quabodepistat片Otsuka Pharmaceutical Co., Ltd.1JXHL2500130JSB462片Novartis Pharma AG1JXHL2500129JSB462片Novartis Pharma AG1JXHL2500128TAR-210Janssen Research & Development, LLC2.2;2.4JXHL2500125镥(177Lu)vipivotide tetraxetan注射液Novartis Pharma AG2.4JXHL2500127BMS-986165片Bristol-Myers Squibb Company2.4JXHL2500124BMS-986165片Bristol-Myers Squibb Company2.4JXHL2500123用于制备放射性药物镓(68Ga)gozetotide注射液的药盒Novartis Europharm Limited5.1JXHL2500126中药相关申请药品名称企业注册分类受理号益胃消瘀颗粒重庆市中药研究院(重庆市中药博物馆)1.1CXZL2500037复方黄杞颗粒浙江九如医药科技有限公司1.1CXZL2500036黄厚止泻滴丸安徽雷允上药业有限公司2.3CXZL2500035苓桂术甘颗粒神威药业集团有限公司3.1CXZS2500024注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗临床申请

2025-04-30

·ioncology

许兰平教授：聚焦全程管理，2025 CSCO造血干细胞移植治疗血液系统疾病指南更新亮点丨2025 CSCO指南会

点击蓝字关注我们编者按：2025年4月18日-19日，由中国临床肿瘤学会（CSCO）和北京市希思科临床肿瘤学研究基金会联合主办的2025 CSCO指南会在济南山东大厦隆重召开。在本次大会上，北京大学人民医院许兰平教授，针对2025 CSCO造血干细胞移植治疗血液系统疾病指南的更新内容进行了深入解读。《肿瘤瞭望-血液时讯》特整理课件精粹，以飨读者。异基因造血干细胞移植（allo-HSCT）是治疗白血病、骨髓增生异常综合征（MDS）、多发性骨髓瘤（MM）、非霍奇金淋巴瘤（NHL）及重型再生障碍性贫血（SAA）等疾病的重要根治手段。随着单倍型移植“北京方案”的建立并在全国范围内推广，allo-HSCT进入“人人皆有供者”的新时代，推动我国移植病例数量持续快速增长。2025版指南立足中国本土的临床实践与科研成果，秉持与时俱进的前瞻视角，从多个方面进行了更新，充分体现持续优化与规范化的发展方向。异基因造血干细胞移植01适应证及时机在异基因造血干细胞移植治疗急性髓系白血病、急性淋巴细胞白血病、慢性髓系白血病、骨髓增生异常综合征、其他B细胞淋巴瘤、T细胞淋巴瘤的适应证中均删去了“≤65岁”的限制。新增“异基因造血干细胞移植治疗地中海贫血的适应证”，具体见下表。02患者及供者评估在患者评估中新增“地中海贫血内容”。03预处理方案在标准清髓性（MAC）预处理中删除了AA部分。新增“地中海贫血移植预处理内容”，见下表。04急性移植物抗宿主病（aGVHD）在aGVHD一线治疗的Ⅱ级推荐中，增加“也可考虑甲泼尼龙1 mg/(kg·d)联合低剂量MTX或低剂量芦可替尼(1B类)”。05慢性移植物抗宿主病（cGVHD）在cGVHD预防的Ⅱ级推荐中，删去了“ATG+PT/CY(2B类)”。在cGVHD的诊断中，新增“眼部GVHD诊断内容”，见下表。在cGVHD一线治疗的Ⅱ级推荐中，删去了“泼尼松+奥法妥木单抗(2B类)”和“泼尼松+伊布替尼(ibrutinib)(2B类)”。在cGVHD二线治疗的Ⅰ级推荐中增加“甲磺酸贝舒地尔(2A类)”，Ⅱ级推荐中增加“西罗莫司(2A类)”和“艾克利单抗(2A类)”，Ⅲ级推荐中增加“本外光分高置换术(ECP)（2C类）”，见下表。新增“cGVHD的患者报告结局评估内容”，见下表。06真菌感染防治在治疗药物的I级推荐中增加“艾沙康唑”，见下表。07病毒感染防治在HBV再激活/感染防治中，增加“干扰素治疗”的Ⅲ级推荐，见下表。08复发防治针对ALL移植后复发的预防，在预处理方案调整的Ⅲ级推荐中，增加“西达本胺联合BUCY预处理方案改善T-ALL/LBL的移植后生存（2B类）”；在靶向药物治疗中，将“Ph-ALL:移植前MRD阳性用贝林妥欧单抗桥接”由Ⅲ级（2B类）推荐调整为Ⅱ级（2A类）推荐，并在Ⅲ级推荐中增加“②移植前CAR-T桥接(MRD阳性)”，见下表。针对MDS移植后复发的预防，在预处理方案中，新增“地西他滨与其他药物(如去甲氧柔红霉素)联合使用可有效降低高危MDS患者移植后的复发率（2A类）”的Ⅱ级推荐，见下表。针对AML移植后复发的抢先治疗，在靶向药物的Ⅲ级推荐中新增“阿伐替尼（3类）”和“去甲基化药物（3类）”；在细胞免疫治疗的I级推荐中新增“改良DLI(2A类)”，见下表。针对ALL移植后复发的抢先治疗，在免疫治疗的Ⅱ级推荐中新增“贝林妥欧单抗（2A类）”，见下表。针对AML移植后复发的治疗，在免疫治疗的Ⅲ级推荐中新增“GO单抗(2A)”；在靶向治疗的Ⅱ级推荐中细化或新增“1.针对FLT3抑制剂吉瑞替尼（1类）和针对FLT3-ITD患者选择索拉非尼联合HMA（2A类）；2.IDH1抑制剂艾伏尼布、奥鲁替尼（2A类）；3.IDH2抑制剂恩西地平（2A类）”；Ⅲ级推荐中新增“2.其他如menin抑制剂(针对KMT2Ar或NPM1突变)（3类）”，见下表。09随访在移植后随访中新增“地中海贫血内容”，见下表。自体造血干细胞移植01适应证针对多发性骨髓瘤自体造血干细胞移植的适应证，将肾功能评估I级推荐中的“血30ml/min≤Cr<60ml/min且尿量正常时，预处理剂量减量(马法兰剂量减为140mg/M2)”和“血Cr<30ml/min，权衡移植利弊”分别调整为Ⅱ级、Ⅲ级推荐，见下表。专家简介许兰平教授北京大学人民医院国家血液系统疾病临床医学研究中心北京大学人民医院血液科副主任、主任医师、博导海峡两岸医药卫生交流协会第三届、第四届理事会常务理事，第二届、第三届血液学专委会主任委员中华骨髓库北京分库第三届专家委员会主任委员中国研究型医院学会细胞研究与治疗专委会常务委员中国医疗保健国际交流促进会临床微生物与感染分会委员中国造血干细胞捐献者资料库第八届、第九届专家委员会委员《白血病.淋巴瘤》《中华老年多器官杂志》《中华血液学杂志》杂志编委2014、2017位两次列国家科学技术进步奖二等奖获奖者名单主要研究方向：造血干细胞移植治疗骨髓衰竭性疾病的研究责任作者或第一作者发表SCI文章50余篇，共同作者参与发表文章500余篇，参与编写教材或论著十余次（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

CSCO会议临床1期

100 项与甲磺酸贝舒地尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11815 D11816	-	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性移植物抗宿主病	美国	Kadmon Pharmaceuticals LLC	2021-07-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
同种异体移植排斥反应	临床3期	美国	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	中国	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	澳大利亚	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	奥地利	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	比利时	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	加拿大	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	捷克	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	丹麦	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	芬兰	Sanofi	2023-10-10
同种异体移植排斥反应	临床3期	法国	Sanofi	2023-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ROCKREAL (EHA2025)	临床2期	慢性移植物抗宿主病	196	Belumosudil	壓壓鬱憲淵淵範鏇構製(鹽鑰醖醖淵襯繭壓築鹹) = 遞範鑰襯鑰鹹遞獵遞願網襯遞獵顧顧構壓窪選 (簾繭鑰壓齋繭鑰鑰構製, 167 ~ 667)	积极	2025-05-14
ROCKREAL (EHA2025)	临床2期	慢性移植物抗宿主病	196	Best Available Therapy (BAT)	壓壓鬱憲淵淵範鏇構製(鹽鑰醖醖淵襯繭壓築鹹) = 窪構積餘鬱餘簾壓鹹膚網襯遞獵顧顧構壓窪選 (簾繭鑰壓齋繭鑰鑰構製, 130 ~ 685)	积极	2025-05-14
NCT05305989 (CTgov)	临床2期	慢性移植物抗宿主病	23	Belumosudil (Belumosudil 200 mg QD)	醖遞廠顧鏇願積製膚醖(齋餘衊繭網鏇齋範願壓) = 憲願廠壓製鹹窪襯壓積鹽鑰衊顧糧簾壓壓積獵 (艱獵鏇鹹蓋鹽製顧夢醖, 選餘餘願觸簾餘餘艱製 ~ 遞餘窪鬱範蓋鹹膚憲廠) 更多	-	2025-05-02
NCT05305989 (CTgov)	临床2期	慢性移植物抗宿主病	23	Belumosudil (Belumosudil 200 mg BID)	醖遞廠顧鏇願積製膚醖(齋餘衊繭網鏇齋範願壓) = 範淵積襯艱獵製築遞廠鹽鑰衊顧糧簾壓壓積獵 (艱獵鏇鹹蓋鹽製顧夢醖, 網鬱餘網簾積醖遞齋淵 ~ 網鹽鹹齋繭淵簾夢廠淵) 更多	-	2025-05-02
NCT03919799 (Pubmed \| Rheumatology (Oxford))	临床2期	弥漫性硬皮病 FOXP3 \| STAT3 \| IL23A ... 更多	-	Belumosudil 200 mg QD	顧網壓齋衊膚範齋艱夢(膚醖醖鏇簾齋積積膚艱) = trends of decreased fibrosis biomarker levels were seen in belumosudil-treated group vs placebo 築鹹觸壓製鹽憲鏇鹽願 (鬱窪廠製顧簾膚簾糧積 )	不佳	2025-03-14
NCT03919799 (Pubmed \| Rheumatology (Oxford))	临床2期	弥漫性硬皮病 FOXP3 \| STAT3 \| IL23A ... 更多	-	Belumosudil 200 mg BID		不佳	2025-03-14
NCT03640481 (KD025-213 \| ROCKstar Study \| ROCKstar, CTgov)	临床2期	慢性移植物抗宿主病	159	Belumosudil (KD025) (Adolescent Arm A: Belumosudil 200 mg QD)	醖齋鏇築鹹糧鑰網淵鏇 = 顧醖衊鹽餘顧窪簾遞築觸繭鑰網繭鹽襯鑰鏇蓋 (餘築選構鹹鏇糧觸選積, 鑰選憲醖齋衊糧簾醖廠 ~ 遞膚簾鏇選顧糧繭醖膚) 更多	-	2024-12-12
NCT03640481 (KD025-213 \| ROCKstar Study \| ROCKstar, CTgov)	临床2期	慢性移植物抗宿主病	159	Belumosudil (KD025) (Adolescent Arm B: Belumosudil 200 mg BID)	醖齋鏇築鹹糧鑰網淵鏇 = 夢憲網艱夢廠簾鹹鬱積觸繭鑰網繭鹽襯鑰鏇蓋 (餘築選構鹹鏇糧觸選積, 餘遞醖鏇製築鑰鹽觸鏇 ~ 廠簾積築齋膚襯窪網艱) 更多	-	2024-12-12
ASH2024	N/A	慢性移植物抗宿主病	-	Belumosudil	鹽繭齋齋願鏇蓋觸醖製(鑰餘淵選餘衊壓選積鏇) = 壓憲襯艱蓋積顧糧遞願鹹範糧選壓壓製簾醖衊 (範簾遞願憲糧選夢醖廠 ) 更多	-	2024-12-08
KD-025-2134 (EHA2024) 人工标引	N/A	类固醇难治性移植物抗宿主病	45	Belumosudil	繭膚艱襯獵鬱願範鹹鑰(鹽壓顧襯壓膚網艱糧餘) = 醖蓋簾積繭鏇鑰憲築衊鹹鏇構觸繭膚鬱淵鑰獵 (膚襯衊醖餘顧憲鏇觸醖 ) 更多	积极	2024-05-14
JPRN-jRCT2011210041 (EHA 12024 \| EHA 22024) 人工标引	临床3期	慢性移植物抗宿主病	21	BelumosudilBelumosudil 200 mg	積積艱淵積鏇鑰觸遞觸(遞蓋獵製夢鬱鬱憲餘積) = 鑰糧齋繭齋憲齋鏇範鏇構鏇糧艱鑰窪壓願窪鏇 (鏇範選簾鏇簾餘選範餘, 63.66 ~ 96.95) 更多	积极	2024-05-14
EHA2024	N/A	移植物抗宿主病	35	Belumosudil	鏇廠鹹製鬱壓艱衊膚衊(衊顧憲網構憲艱選鏇蓋) = 2 patients where additional treatment for cGvHD had to be initiated 網餘糧繭餘艱網觸製廠 (憲艱築窪遞鬱顧範齋醖 ) 更多	积极	2024-05-14
NCT04930562 (Pubmed) 人工标引	临床2期	慢性移植物抗宿主病二线	30	Belumosudil 200 mg	壓齋夢壓觸製鑰製糧鑰(淵膚積簾觸齋餘構襯齋) = 積獵顧醖膚簾襯糧鑰膚網鬱壓觸窪遞鏇願餘壓 (憲積選膚觸鏇廠積繭願, 54.1 ~ 87.7) 更多	积极	2024-03-26
Tandem Meetings ASTCT and CIBMTR2024 人工标引	N/A	类固醇难治性移植物抗宿主病	14	Belumosudil-Ruxolitinib (bel-rux) dual therapy	選願窪夢鹹壓餘餘淵窪(選簾廠鹹獵簾醖鬱簾蓋) = 構鏇構繭壓獵範鏇壓範選獵願壓築艱壓憲網製 (獵醖鹽鹽築糧獵顧齋衊 ) 更多	积极	2024-02-01